These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 28110415)

  • 21. Combination versus monotherapy as definitive treatment for Pseudomonas aeruginosa bacteraemia: a multicentre retrospective observational cohort study.
    Babich T; Naucler P; Valik JK; Giske CG; Benito N; Cardona R; Rivera A; Pulcini C; Abdel Fattah M; Haquin J; MacGowan A; Grier S; Gibbs J; Chazan B; Yanovskay A; Ami RB; Landes M; Nesher L; Zaidman-Shimshovitz A; McCarthy K; Paterson DL; Tacconelli E; Buhl M; Mauer S; Rodriguez-Bano J; Morales I; Oliver A; Ruiz de Gopegui E; Cano A; Machuca I; Gozalo-Marguello M; Martinez LM; Gonzalez-Barbera EM; Alfaro IG; Salavert M; Beovic B; Saje A; Mueller-Premru M; Pagani L; Vitrat V; Kofteridis D; Zacharioudaki M; Maraki S; Weissman Y; Paul M; Dickstein Y; Leibovici L; Yahav D
    J Antimicrob Chemother; 2021 Jul; 76(8):2172-2181. PubMed ID: 33993273
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of adequate empirical combination therapy on mortality from bacteremic Pseudomonas aeruginosa pneumonia.
    Park SY; Park HJ; Moon SM; Park KH; Chong YP; Kim MN; Kim SH; Lee SO; Kim YS; Woo JH; Choi SH
    BMC Infect Dis; 2012 Nov; 12():308. PubMed ID: 23157735
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome.
    Kang CI; Kim SH; Kim HB; Park SW; Choe YJ; Oh MD; Kim EC; Choe KW
    Clin Infect Dis; 2003 Sep; 37(6):745-51. PubMed ID: 12955633
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibiotic therapy and clinical outcomes of Pseudomonas aeruginosa (PA) bacteraemia.
    Tan SH; Teng CB; Ng TM; Lye DC
    Ann Acad Med Singap; 2014 Nov; 43(11):526-34. PubMed ID: 25523856
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibiotic treatment adequacy and death among patients with Pseudomonas aeruginosa airway infection.
    Eklöf J; Gliese KM; Ingebrigtsen TS; Bodtger U; Jensen JS
    PLoS One; 2019; 14(12):e0226935. PubMed ID: 31891624
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint.
    Tam VH; Gamez EA; Weston JS; Gerard LN; Larocco MT; Caeiro JP; Gentry LO; Garey KW
    Clin Infect Dis; 2008 Mar; 46(6):862-7. PubMed ID: 18279040
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of a combination antibiogram for Pseudomonas aeruginosa bacteremia in an oncology population.
    Smith ZR; Tajchman SK; Dee BM; Bruno JJ; Qiao W; Tverdek FP
    J Oncol Pharm Pract; 2016 Jun; 22(3):409-15. PubMed ID: 25956419
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk factors for pan-resistant Pseudomonas aeruginosa bacteremia and the adequacy of antibiotic therapy.
    Tuon FF; Gortz LW; Rocha JL
    Braz J Infect Dis; 2012; 16(4):351-6. PubMed ID: 22846123
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical characteristics and risk factors for mortality in cefepime-resistant Pseudomonas aeruginosa bacteremia.
    Su TY; Ye JJ; Hsu PC; Wu HF; Chia JH; Lee MH
    J Microbiol Immunol Infect; 2015 Apr; 48(2):175-82. PubMed ID: 24064286
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment.
    Micek ST; Lloyd AE; Ritchie DJ; Reichley RM; Fraser VJ; Kollef MH
    Antimicrob Agents Chemother; 2005 Apr; 49(4):1306-11. PubMed ID: 15793102
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pseudomonas aeruginosa bloodstream infections in children: a 9-year retrospective study.
    Pilmis B; Alby-Laurent F; Fasola ML; Seegers V; Guery R; Guet-Revillet H; Postaire M; Toubiana J; Bille E; Lortholary O; Zahar JR
    Eur J Pediatr; 2020 Aug; 179(8):1247-1254. PubMed ID: 32080759
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia: clinical impact of antimicrobial resistance on outcome.
    Joo EJ; Kang CI; Ha YE; Kang SJ; Park SY; Chung DR; Peck KR; Lee NY; Song JH
    Microb Drug Resist; 2011 Jun; 17(2):305-12. PubMed ID: 21381966
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Previous ciprofloxacin exposure is associated with resistance to beta-lactam antibiotics in subsequent Pseudomonas aeruginosa bacteremic isolates.
    López-Dupla M; Martínez JA; Vidal F; Almela M; Soriano A; Marco F; López J; Olona M; Mensa J
    Am J Infect Control; 2009 Nov; 37(9):753-8. PubMed ID: 19487049
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pseudomonas aeruginosa bacteraemia in burns patients: Risk factors and outcomes.
    Mahar P; Padiglione AA; Cleland H; Paul E; Hinrichs M; Wasiak J
    Burns; 2010 Dec; 36(8):1228-33. PubMed ID: 20965109
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination therapy for treatment of Pseudomonas aeruginosa bloodstream infections.
    Tschudin-Sutter S; Fosse N; Frei R; Widmer AF
    PLoS One; 2018; 13(9):e0203295. PubMed ID: 30235247
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Carbapenem-Resistant Pseudomonas aeruginosa Bacteremia: Risk Factors for Mortality and Microbiologic Treatment Failure.
    Buehrle DJ; Shields RK; Clarke LG; Potoski BA; Clancy CJ; Nguyen MH
    Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27821456
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Integrating rapid diagnostics and antimicrobial stewardship improves outcomes in patients with antibiotic-resistant Gram-negative bacteremia.
    Perez KK; Olsen RJ; Musick WL; Cernoch PL; Davis JR; Peterson LE; Musser JM
    J Infect; 2014 Sep; 69(3):216-25. PubMed ID: 24841135
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pseudomonas aeruginosa bacteremia: resistance to antibiotics, risk factors, and patient mortality.
    Vitkauskienė A; Skrodenienė E; Dambrauskienė A; Macas A; Sakalauskas R
    Medicina (Kaunas); 2010; 46(7):490-5. PubMed ID: 20966623
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis.
    Bilton D; Henig N; Morrissey B; Gotfried M
    Chest; 2006 Nov; 130(5):1503-10. PubMed ID: 17099030
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outcomes of empiric aminoglycoside monotherapy for Pseudomonas aeruginosa bacteremia.
    Phe K; Bowers DR; Babic JT; Tam VH
    Diagn Microbiol Infect Dis; 2019 Apr; 93(4):346-348. PubMed ID: 30522794
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.